BioMatrix Scientific Group, Inc. (OTCMKTS:BMSN) Riles Investors Again with Drug Test Results

BioMatrix Scientific Group, Inc. (OTCMKTS:BMSN) is still pressed down, but a piece of news caused buying to revive. BMSN grew by more than 18% on Wednesday, reaching $0.0019 on buying volumes above $476,000. BMSN enticed investors again with a PR message announcing success with animal model trials on one of its drug proposals, HemaXellerate I TM.

Of course, an animal model is still quite far from ensuring earnings, or even allowing the drug to come to the market. Still, for BMSN those are the highest buying volumes since the summer. The ticker is a long-defunct promotion, which turned into a double-zero bid, trading choppily despite snippets of positive news. This stock has long lost its direction, but has its days of separate strong earnings.

Now, BMSN opened up on Thursday with a bit of drama, starting the day upward and reversing the trend. But this is not unusual behavior- periodically, BMSN spikes when volumes pick up, only to continue drifting on less active trading.

BMSN was abandoned by promoters at the end of September, and it has not been above the penny levels since the spring of this year. The ticker, without a promotion or publicity, has touched triple-zeroes easily in a sharp fall at the end of last year. Now, BMSN is on a slow downward trend, but it takes more care of awareness with publicity and hopeful announcements on its innovative therapies.

If you are looking for a more cheerful drug developer, Applied DNA Sciences, Inc. (OTCMKTS:APDN) is trending right now, on a few days of solid buying and climbing. APDN already reached 15 cents, adding a third to its price.

Elite Pharmaceuticals, Inc. (OTCBB:ELTP) started off as the different pharmaceutical bid, only to retreat and cause painful losses. So while BMSN is a known risk factor, more hopeful companies never guarantee a good development.

If you are still willing to try out BMSN, keep in mind that this ticker is unpredictable, moving in opposing directions quite often, and easily wiping out the gains. Do not fall outright for the longer-term promises, and avoid investing sums that you cannot afford to lose on the inevitable corrections.